Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis
暂无分享,去创建一个
M. Mack | Chieh-Yu Lin | J. Moslehi | H. Luehmann | Ruijun He | J. Amrute | Andrea L Bredemeyer | Guoshuai Feng | K. Amancherla | K. Lavine | Lulu Lai | Ana Villanueva | Pan Ma | Jing Liu | Antanisha Parks | G. Heo | Yongjian Liu | Jesús Jiménez | Geetika Bajapa | Deborah Sultan | Juan Qin
[1] C. Morélot-Panzini,et al. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. , 2023, Cancer discovery.
[2] D. Hughes,et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis , 2022, Cell reports.
[3] J. Neal,et al. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis , 2022, Circulation.
[4] P. Muñoz,et al. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity , 2022, Journal of experimental & clinical cancer research : CR.
[5] John O. Prior,et al. 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis , 2021, Journal for ImmunoTherapy of Cancer.
[6] D. Schadendorf,et al. Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. , 2021, European heart journal.
[7] P. Funchain,et al. Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms , 2021, Frontiers in Cardiovascular Medicine.
[8] L. Heinzerling,et al. Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation , 2021, Cancers.
[9] Jing Wang,et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. , 2020, Cancer discovery.
[10] Z. Qin,et al. Temporary blockade of interferon-γ ameliorates doxorubicin-induced cardiotoxicity without influencing the anti-tumor effect. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[11] Lihua Zhang,et al. Inference and analysis of cell-cell communication using CellChat , 2020, Nature Communications.
[12] Hannah L Williams,et al. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy , 2020, Cell.
[13] R. Gropler,et al. Targeted PET Imaging of Chemokine Receptor 2–Positive Monocytes and Macrophages in the Injured Heart , 2020, The Journal of Nuclear Medicine.
[14] D. Pisetsky,et al. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors , 2019, Rheumatology.
[15] Douglas B. Johnson,et al. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. , 2019, The New England journal of medicine.
[16] P. Sapra,et al. Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors , 2019, Clinical Cancer Research.
[17] Yi Su,et al. Molecular Imaging Visualizes Recruitment of Inflammatory Monocytes and Macrophages to the Injured Heart , 2019, Circulation research.
[18] D. Pe’er,et al. Characterization of cell fate probabilities in single-cell data with Palantir , 2019, Nature Biotechnology.
[19] I. Blasig,et al. Doxorubicin‐induced cardiotoxicity involves IFNγ‐mediated metabolic reprogramming in cardiomyocytes , 2019, The Journal of pathology.
[20] Maxim N. Artyomov,et al. Tissue Resident CCR2− and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury , 2019, Circulation research.
[21] M. Zaidi,et al. The Interferon-Gamma Paradox in Cancer. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[22] F. Ginhoux,et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction , 2018, Nature Immunology.
[23] M. Nahrendorf,et al. Cardioimmunology: the immune system in cardiac homeostasis and disease , 2018, Nature Reviews Immunology.
[24] D. Kreisel,et al. The Human Heart Contains Distinct Macrophage Subsets with Divergent Origins and Functions , 2018, Nature Medicine.
[25] Sumanth D. Prabhu,et al. CCR2+ Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload , 2018, JACC. Basic to translational science.
[26] Hideo Baba,et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.
[27] J. Wolchok,et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Rong Chen,et al. Angiotensin II–C–C chemokine receptor2/5 axis‐dependent monocyte/macrophage recruitment contributes to progression of experimental autoimmune myocarditis , 2017, Microbiology and immunology.
[29] D. Bonaduce,et al. Cardiotoxicity of immune checkpoint inhibitors , 2017, ESMO Open.
[30] J. Aerts,et al. SCENIC: Single-cell regulatory network inference and clustering , 2017, Nature Methods.
[31] J. Seidman,et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.
[32] F. Zouein,et al. The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart , 2016, Journal of immunology research.
[33] Hussein Tawbi,et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy , 2016, Journal of Immunotherapy for Cancer.
[34] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[35] D. Mann,et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart , 2014, Proceedings of the National Academy of Sciences.
[36] G. Randolph,et al. Origin and functions of tissue macrophages. , 2014, Immunity.
[37] Ansuman T. Satpathy,et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. , 2014, Immunity.
[38] S. Moestrup,et al. CD163-L1 Is an Endocytic Macrophage Protein Strongly Regulated by Mediators in the Inflammatory Response , 2012, The Journal of Immunology.
[39] T. Okazaki,et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. , 2010, International immunology.
[40] Y. Talke,et al. Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis. , 2007, Arthritis and rheumatism.
[41] R. Rabin,et al. CXCR3 Is Induced Early on the Pathway of CD4+ T Cell Differentiation and Bridges Central and Peripheral Functions 12 , 2003, The Journal of Immunology.
[42] P. Hokland,et al. Interferon enhances the antibody-dependent cellular cytotoxicity (ADCC) of human polymorphonuclear leukocytes. , 1981, Journal of immunology.
[43] Jennifer L. Guerriero. Macrophages: Their Untold Story in T Cell Activation and Function. , 2019, International review of cell and molecular biology.
[44] T. O’Toole,et al. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. , 2014, Methods.